Herantis Pharma
1.86 EUR
+9.42 %
4,561 following
Corporate customer
HRTIS
First North Finland
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Investor consensus
+9.42 %
+15.40 %
-16.68 %
-8.92 %
-15.55 %
+35.62 %
-10.67 %
-23.69 %
-81.55 %
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Read moreMarket cap
49.24M EUR
Turnover
148.07K EUR
P/E (adj.) (26e)
-14.23
EV/EBIT (adj.) (26e)
-12.65
P/B (26e)
6.5
EV/S (26e)
5,501.79
Dividend yield-% (26e)
-
Coverage
Analyst
Revenue and EBIT-%
Revenue K
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
20.8
2026
Interim report Q2'26
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types
Redeye: Herantis Pharma: CEO Antti Vuolanto is interviewed by Redeye’s analyst
Notice to the Annual General Meeting of Herantis Pharma Plc
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
